{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:02:47Z","timestamp":1780498967508,"version":"3.54.1"},"reference-count":88,"publisher":"Siapec Servizi Srl","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologica"],"DOI":"10.32074\/1591-951x-1092","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T07:41:34Z","timestamp":1749195694000},"page":"73-83","source":"Crossref","is-referenced-by-count":4,"title":["Immunotherapy in recurrent\/metastatic head and neck squamous cell carcinoma: PD-L1 and beyond"],"prefix":"10.32074","volume":"117","author":[{"given":"Andrea","family":"Ascione","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Botticelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Leopizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Cerbelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Bellavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Della Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"d\u2019Amati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Cerbelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21774","published-online":{"date-parts":[[2025,5]]},"reference":[{"key":"10.32074\/1591-951X-1092_ref1","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. https:\/\/doi.org\/10.3322\/caac.21660. Epub 2021 Feb 4. PMID: 33538338.","DOI":"10.3322\/caac.21660"},{"key":"10.32074\/1591-951X-1092_ref2","doi-asserted-by":"crossref","unstructured":"Muzaffar J, Bari S, Kirtane K, et al. Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2021 Jan 18;13(2):338. https:\/\/doi.org\/10.3390\/cancers13020338. PMID: 33477635; PMCID: PMC7831487.","DOI":"10.3390\/cancers13020338"},{"key":"10.32074\/1591-951X-1092_ref3","doi-asserted-by":"crossref","unstructured":"Botticelli A, Mezi S, Pomati G, et al. The 5-Ws of immunotherapy in head and neck cancer. Crit Rev Oncol Hematol. 2020 Sep;153:103041. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103041. Epub 2020 Jun 30. PMID: 32629362.","DOI":"10.1016\/j.critrevonc.2020.103041"},{"key":"10.32074\/1591-951X-1092_ref4","doi-asserted-by":"crossref","unstructured":"Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2008 Apr;83(4):489-501. https:\/\/doi.org\/10.4065\/83.4.489. Erratum in: Mayo Clin Proc. 2008 May;83(5):604. PMID: 18380996.","DOI":"10.4065\/83.4.489"},{"key":"10.32074\/1591-951X-1092_ref5","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7-34. https:\/\/doi.org\/10.3322\/caac.21551. Epub 2019 Jan 8. PMID: 30620402.","DOI":"10.3322\/caac.21551"},{"key":"10.32074\/1591-951X-1092_ref6","doi-asserted-by":"crossref","unstructured":"Botticelli A, Cirillo A, Strigari L, et al. Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis. Front Immunol. 2021 Aug 9;12:705096. https:\/\/doi.org\/10.3389\/fimmu.2021.705096. PMID: 34434192; PMCID: PMC8380817.","DOI":"10.3389\/fimmu.2021.705096"},{"key":"10.32074\/1591-951X-1092_ref7","doi-asserted-by":"crossref","unstructured":"Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008 Sep 11;359(11):1116-27. https:\/\/doi.org\/10.1056\/NEJMoa0802656. PMID: 18784101.","DOI":"10.1056\/NEJMoa0802656"},{"key":"10.32074\/1591-951X-1092_ref8","doi-asserted-by":"crossref","unstructured":"Guigay J, Aup\u00e9rin A, Fayette J, et al. GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2021 Apr;22(4):463-475. https:\/\/doi.org\/10.1016\/S1470-2045(20)30755-5. Epub 2021 Mar 5. PMID: 33684370.","DOI":"10.1016\/S1470-2045(20)30755-5"},{"key":"10.32074\/1591-951X-1092_ref9","doi-asserted-by":"crossref","unstructured":"El Rassy E, Assi T, Bakouny Z, et al. Comparison of second-line treatments of recurrent and\/or metastatic squamous cell carcinoma of the head and neck. Future Oncol. 2019 Mar;15(8):909-923. https:\/\/doi.org\/10.2217\/fon-2018-0663. Epub 2019 Jan 23. PMID: 30669875.","DOI":"10.2217\/fon-2018-0663"},{"key":"10.32074\/1591-951X-1092_ref10","doi-asserted-by":"crossref","unstructured":"Fasano M, Corte CMD, Liello RD, et al. Immunotherapy for head and neck cancer: Present and future. Crit Rev Oncol Hematol. 2022 Jun;174:103679. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103679. Epub 2022 Apr 6. PMID: 35395371.","DOI":"10.1016\/j.critrevonc.2022.103679"},{"key":"10.32074\/1591-951X-1092_ref11","doi-asserted-by":"crossref","unstructured":"Marin-Acevedo JA, Dholaria B, Soyano AE, et al. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018 Mar 15;11(1):39. https:\/\/doi.org\/10.1186\/s13045-018-0582-8. PMID: 29544515; PMCID: PMC5856308.","DOI":"10.1186\/s13045-018-0582-8"},{"key":"10.32074\/1591-951X-1092_ref12","doi-asserted-by":"crossref","unstructured":"Wang Y, Yang S, Wan L, et al. New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review). Int J Oncol. 2023 Jul;63(1):86. https:\/\/doi.org\/10.3892\/ijo.2023.5534. Epub 2023 Jun 16. PMID: 37326100; PMCID: PMC10308343.","DOI":"10.3892\/ijo.2023.5534"},{"key":"10.32074\/1591-951X-1092_ref13","doi-asserted-by":"crossref","unstructured":"Park JC, Krishnakumar HN, Saladi SV. Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma. Curr Oncol. 2022 Jun 8;29(6):4185-4198. https:\/\/doi.org\/10.3390\/curroncol29060334. PMID: 35735443; PMCID: PMC9221564.","DOI":"10.3390\/curroncol29060334"},{"key":"10.32074\/1591-951X-1092_ref14","doi-asserted-by":"crossref","unstructured":"Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016 Jul;17(7):956-965. https:\/\/doi.org\/10.1016\/S1470-2045(16)30066-3. Epub 2016 May 27. PMID: 27247226.","DOI":"10.1016\/S1470-2045(16)30066-3"},{"key":"10.32074\/1591-951X-1092_ref15","doi-asserted-by":"crossref","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016 Nov 10;375(19):1856-1867. https:\/\/doi.org\/10.1056\/NEJMoa1602252. Epub 2016 Oct 8. PMID: 27718784; PMCID: PMC5564292.","DOI":"10.1056\/NEJMoa1602252"},{"key":"10.32074\/1591-951X-1092_ref16","doi-asserted-by":"crossref","unstructured":"Hsieh RW, Borson S, Tsagianni A, et al. Immunotherapy in Recurrent\/Metastatic Squamous Cell Carcinoma of the Head and Neck. Front Oncol. 2021 Sep 1;11:705614. https:\/\/doi.org\/10.3389\/fonc.2021.705614. PMID: 34540672; PMCID: PMC8440813.","DOI":"10.3389\/fonc.2021.705614"},{"key":"10.32074\/1591-951X-1092_ref17","doi-asserted-by":"crossref","unstructured":"Sacco AG, Cohen EE. Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2015 Oct 10;33(29):3305-13. https:\/\/doi.org\/10.1200\/JCO.2015.62.0963. Epub 2015 Sep 8. PMID: 26351341.","DOI":"10.1200\/JCO.2015.62.0963"},{"key":"10.32074\/1591-951X-1092_ref18","doi-asserted-by":"crossref","unstructured":"Burtness B, Harrington KJ, Greil R, et al. KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019 Nov 23;394(10212):1915-1928. https:\/\/doi.org\/10.1016\/S0140-6736(19)32591-7. Epub 2019 Nov 1. Erratum in: Lancet. 2020 Jan 25;395(10220):272. https:\/\/doi.org\/10.1016\/S0140-6736(20)30116-1. Erratum in: Lancet. 2020 Feb 22;395(10224):564. https:\/\/doi.org\/10.1016\/S0140-6736(20)30254-3. Erratum in: Lancet. 2021 Jun 12;397(10291):2252. https:\/\/doi.org\/10.1016\/S0140-6736(21)01119-3. PMID: 31679945.","DOI":"10.1016\/S0140-6736(21)01119-3"},{"key":"10.32074\/1591-951X-1092_ref19","doi-asserted-by":"crossref","unstructured":"Huang Z, Zheng S, Ding S, et al. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1\/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials. J Cancer Res Ther. 2021 Jul;17(3):676-687. https:\/\/doi.org\/10.4103\/jcrt.JCRT_1606_20. PMID: 34269299.","DOI":"10.4103\/jcrt.JCRT_1606_20"},{"key":"10.32074\/1591-951X-1092_ref20","doi-asserted-by":"crossref","unstructured":"Kim H, Kwon M, Kim B, et al. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea. BMC Cancer. 2020 Aug 5;20(1):727. https:\/\/doi.org\/10.1186\/s12885-020-07214-4. PMID: 32758163; PMCID: PMC7405432.","DOI":"10.1186\/s12885-020-07214-4"},{"key":"10.32074\/1591-951X-1092_ref21","doi-asserted-by":"crossref","unstructured":"Cohen EEW, Bell RB, Bifulco CB, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019 Jul 15;7(1):184. https:\/\/doi.org\/10.1186\/s40425-019-0662-5. PMID: 31307547; PMCID: PMC6632213.","DOI":"10.1186\/s40425-019-0662-5"},{"key":"10.32074\/1591-951X-1092_ref22","doi-asserted-by":"crossref","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol. 2022 Apr 24;29(5):3044-3060. https:\/\/doi.org\/10.3390\/curroncol29050247. PMID: 35621637; PMCID: PMC9139602.","DOI":"10.3390\/curroncol29050247"},{"key":"10.32074\/1591-951X-1092_ref23","doi-asserted-by":"crossref","unstructured":"Oliva M, Spreafico A, Taberna M, et al. Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma. Ann Oncol. 2019 Jan 1;30(1):57-67. https:\/\/doi.org\/10.1093\/annonc\/mdy507. PMID: 30462163; PMCID: PMC6336003.","DOI":"10.1093\/annonc\/mdy507"},{"key":"10.32074\/1591-951X-1092_ref24","doi-asserted-by":"crossref","unstructured":"Emancipator K, Huang L, Aurora-Garg D, et al. Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. Mod Pathol. 2021 Mar;34(3):532-541. https:\/\/doi.org\/10.1038\/s41379-020-00710-9. Epub 2020 Nov 25. PMID: 33239737.","DOI":"10.1038\/s41379-020-00710-9"},{"key":"10.32074\/1591-951X-1092_ref25","doi-asserted-by":"crossref","unstructured":"Prince EA, Sanzari JK, Pandya D, et al. Analytical Concordance of PD-L1 Assays Utilizing Antibodies From FDA-Approved Diagnostics in Advanced Cancers: A Systematic Literature Review. JCO Precis Oncol. 2021 Jun 8;5:953-973. https:\/\/doi.org\/10.1200\/PO.20.00412. PMID: 34136742; PMCID: PMC8202559.","DOI":"10.1200\/PO.20.00412"},{"key":"10.32074\/1591-951X-1092_ref26","doi-asserted-by":"crossref","unstructured":"De Ruiter EJ, Mulder FJ, Koomen BM, et al. Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC). Mod Pathol. 2021 Jun;34(6):1125-1132. https:\/\/doi.org\/10.1038\/s41379-020-0644-7. Epub 2020 Aug 5. PMID: 32759978.","DOI":"10.1038\/s41379-020-0644-7"},{"key":"10.32074\/1591-951X-1092_ref27","doi-asserted-by":"crossref","unstructured":"Cerbelli B, Girolami I, Eccher A, et al. Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study. Histopathology. 2022 Jan;80(2):397-406. https:\/\/doi.org\/10.1111\/his.14562. Epub 2021 Nov 11. PMID: 34496080; PMCID: PMC9299113.","DOI":"10.1111\/his.14562"},{"key":"10.32074\/1591-951X-1092_ref28","doi-asserted-by":"crossref","unstructured":"Guerini Rocco E, Eccher A, Girolami I, et al. Concordance between Three PD-L1 Immunohistochemical Assays in Head and Neck Squamous Cell Carcinoma (HNSCC) in a Multicenter Study. Diagnostics (Basel). 2022 Feb 13;12(2):477. https:\/\/doi.org\/10.3390\/diagnostics12020477. PMID: 35204568; PMCID: PMC8871075.","DOI":"10.3390\/diagnostics12020477"},{"key":"10.32074\/1591-951X-1092_ref29","doi-asserted-by":"crossref","unstructured":"Nuti S, Zhang Y, Zerrouki N, et al. High interobserver and intraobserver reproducibility among pathologists assessing PD-L1 CPS across multiple indications. Histopathology. 2022 Dec;81(6):732-741. https:\/\/doi.org\/10.1111\/his.14775. Epub 2022 Sep 23. PMID: 35993150.","DOI":"10.1111\/his.14775"},{"key":"10.32074\/1591-951X-1092_ref30","doi-asserted-by":"crossref","unstructured":"Paolino G, Pantanowitz L, Barresi V, et al. PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy. Pathol Res Pract. 2021 Oct;226:153605. https:\/\/doi.org\/10.1016\/j.prp.2021.153605. Epub 2021 Sep 1. PMID: 34530257.","DOI":"10.1016\/j.prp.2021.153605"},{"key":"10.32074\/1591-951X-1092_ref31","doi-asserted-by":"crossref","unstructured":"Ambrosini-Spaltro A, Limarzi F, Gaudio M, et al. PD-L1 expression in head and neck carcinoma by combined positive score: a comparison among preoperative biopsy, tumor resection, and lymph node metastasis. Virchows Arch. 2022 Jul;481(1):93-99. https:\/\/doi.org\/10.1007\/s00428-022-03322-7. Epub 2022 Apr 14. PMID: 35420378.","DOI":"10.1007\/s00428-022-03322-7"},{"key":"10.32074\/1591-951X-1092_ref32","doi-asserted-by":"crossref","unstructured":"Kalpakoff M, Hund S, Musser J, et al. Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx. Appl Immunohistochem Mol Morphol. 2021 Oct 1;29(9):667-673. https:\/\/doi.org\/10.1097\/PAI.0000000000000941. PMID: 33973887; PMCID: PMC8505133.","DOI":"10.1097\/PAI.0000000000000941"},{"key":"10.32074\/1591-951X-1092_ref33","doi-asserted-by":"crossref","unstructured":"Scorer P, Scott M, Lawson N, et al. Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay. Diagn Pathol. 2018 Jul 24;13(1):47. https:\/\/doi.org\/10.1186\/s13000-018-0725-9. PMID: 30041679; PMCID: PMC6058354.","DOI":"10.1186\/s13000-018-0725-9"},{"key":"10.32074\/1591-951X-1092_ref34","doi-asserted-by":"crossref","unstructured":"Bill R, Faquin WC, Pai SI. Assessing PD-L1 Expression in Head and Neck Squamous Cell Carcinoma: Trials and Tribulations. Head Neck Pathol. 2023 Dec;17(4):969-975. https:\/\/doi.org\/10.1007\/s12105-023-01590-6. Epub 2023 Nov 6. PMID: 37930471; PMCID: PMC10739626.","DOI":"10.1007\/s12105-023-01590-6"},{"key":"10.32074\/1591-951X-1092_ref35","doi-asserted-by":"crossref","unstructured":"Karabajakian A, Bouaoud J, Michon L, et al. Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity. Oral Oncol. 2021 Aug;119:105368. https:\/\/doi.org\/10.1016\/j.oraloncology.2021.105368. Epub 2021 Jun 7. PMID: 34111704.","DOI":"10.1016\/j.oraloncology.2021.105368"},{"key":"10.32074\/1591-951X-1092_ref36","doi-asserted-by":"crossref","unstructured":"Karpathiou G, Vincent M, Dumollard JM, et al. PD-L1 expression in head and neck cancer tissue specimens decreases with time. Pathol Res Pract. 2022 Sep;237:154042. https:\/\/doi.org\/10.1016\/j.prp.2022.154042. Epub 2022 Jul 27. PMID: 35926433.","DOI":"10.1016\/j.prp.2022.154042"},{"key":"10.32074\/1591-951X-1092_ref37","doi-asserted-by":"crossref","unstructured":"Liu Z, Williams M, Stewart J, et al. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma. Cancer Cytopathol. 2022 Feb;130(2):110-119. https:\/\/doi.org\/10.1002\/cncy.22501. Epub 2021 Aug 10. PMID: 34375025; PMCID: PMC8810615.","DOI":"10.1002\/cncy.22501"},{"key":"10.32074\/1591-951X-1092_ref38","doi-asserted-by":"crossref","unstructured":"Paintal AS, Brockstein BE. PD-L1 CPS Scoring Accuracy in Small Biopsies and Aspirate Cell Blocks from Patients with Head and Neck Squamous Cell Carcinoma. Head Neck Pathol. 2020 Sep;14(3):657-665. https:\/\/doi.org\/10.1007\/s12105-019-01097-z. Epub 2019 Nov 13. PMID: 31721075; PMCID: PMC7413953.","DOI":"10.1007\/s12105-019-01097-z"},{"key":"10.32074\/1591-951X-1092_ref39","doi-asserted-by":"crossref","unstructured":"Klempner SJ, Fabrizio D, Bane S, et al. Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. Oncologist. 2020 Jan;25(1):e147-e159. https:\/\/doi.org\/10.1634\/theoncologist.2019-0244. Epub 2019 Oct 2. PMID: 31578273; PMCID: PMC6964127.","DOI":"10.1634\/theoncologist.2019-0244"},{"key":"10.32074\/1591-951X-1092_ref40","doi-asserted-by":"crossref","unstructured":"Jardim DL, Goodman A, de Melo Gagliato D, et al. The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell. 2021 Feb 8;39(2):154-173. https:\/\/doi.org\/10.1016\/j.ccell.2020.10.001. Epub 2020 Oct 29. PMID: 33125859; PMCID: PMC7878292.","DOI":"10.1016\/j.ccell.2020.10.001"},{"key":"10.32074\/1591-951X-1092_ref41","doi-asserted-by":"crossref","unstructured":"Cristescu R, Aurora-Garg D, Albright A, et al. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. J Immunother Cancer. 2022 Jan;10(1):e003091. https:\/\/doi.org\/10.1136\/jitc-2021-003091. PMID: 35101941; PMCID: PMC8804694.","DOI":"10.1136\/jitc-2021-003091"},{"key":"10.32074\/1591-951X-1092_ref42","doi-asserted-by":"crossref","unstructured":"Marcus L, Fashoyin-Aje LA, Donoghue M, et al. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors. Clin Cancer Res. 2021 Sep 1;27(17):4685-4689. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0327. Epub 2021 Jun 3. PMID: 34083238; PMCID: PMC8416776.","DOI":"10.1158\/1078-0432.CCR-21-0327"},{"key":"10.32074\/1591-951X-1092_ref43","doi-asserted-by":"crossref","unstructured":"Rodrigo JP, S\u00e1nchez-Canteli M, Otero-Rosales M, et al. Tumor mutational burden predictability in head and neck squamous cell carcinoma patients treated with immunotherapy: systematic review and meta-analysis. J Transl Med. 2024 Feb 4;22(1):135. https:\/\/doi.org\/10.1186\/s12967-024-04937-x. PMID: 38311741; PMCID: PMC10840180.","DOI":"10.1186\/s12967-024-04937-x"},{"key":"10.32074\/1591-951X-1092_ref44","doi-asserted-by":"crossref","unstructured":"Hanna GJ, Lizotte P, Cavanaugh M, et al. Frameshift events predict anti-PD-1\/L1 response in head and neck cancer. JCI Insight. 2018 Feb 22;3(4):e98811. https:\/\/doi.org\/10.1172\/jci.insight.98811. PMID: 29467336; PMCID: PMC5916245.","DOI":"10.1172\/jci.insight.98811"},{"key":"10.32074\/1591-951X-1092_ref45","doi-asserted-by":"crossref","unstructured":"Yilmaz E, Ismaila N, Bauman JE, et al. Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline. J Clin Oncol. 2023 Feb 10;41(5):1132-1146. https:\/\/doi.org\/10.1200\/JCO.22.02328. Epub 2022 Dec 15. PMID: 36521102.","DOI":"10.1200\/JCO.22.02328"},{"key":"10.32074\/1591-951X-1092_ref46","unstructured":"Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017 Jul 28;357(6349):409-413. https:\/\/doi.org\/10.1126\/science.aan6733. Epub 2017 Jun 8. PMID: 28596308; PMCID: PMC5576142."},{"key":"10.32074\/1591-951X-1092_ref47","doi-asserted-by":"crossref","unstructured":"Wang HC, Yeh TJ, Chan LP, et al. Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice. Int J Mol Sci. 2020 Oct 15;21(20):7621. https:\/\/doi.org\/10.3390\/ijms21207621. PMID: 33076306; PMCID: PMC7589088.","DOI":"10.3390\/ijms21207621"},{"key":"10.32074\/1591-951X-1092_ref48","doi-asserted-by":"crossref","unstructured":"De Schutter H, Spaepen M, Mc Bride WH, et al. The clinical relevance of microsatellite alterations in head and neck squamous cell carcinoma: a critical review. Eur J Hum Genet. 2007 Jul;15(7):734-41. https:\/\/doi.org\/10.1038\/sj.ejhg.5201845. Epub 2007 May 2. PMID: 17473833.","DOI":"10.1038\/sj.ejhg.5201845"},{"key":"10.32074\/1591-951X-1092_ref49","doi-asserted-by":"crossref","unstructured":"Tardy MP, Di Mauro I, Ebran N, et al. Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma. Oral Oncol. 2018 May;80:104-107. https:\/\/doi.org\/10.1016\/j.oraloncology.2018.04.001. Epub 2018 Apr 7. PMID: 29631799.","DOI":"10.1016\/j.oraloncology.2018.04.001"},{"key":"10.32074\/1591-951X-1092_ref50","doi-asserted-by":"crossref","unstructured":"D\u2019Souza G, Dempsey A. The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med. 2011 Oct;53 Suppl 1(Suppl 1):S5-S11. https:\/\/doi.org\/10.1016\/j.ypmed.2011.08.001. PMID: 21962471; PMCID: PMC3287051.","DOI":"10.1016\/j.ypmed.2011.08.001"},{"key":"10.32074\/1591-951X-1092_ref51","doi-asserted-by":"crossref","unstructured":"Starska-Kowarska K. The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer-Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy. Cancers (Basel). 2023 Mar 7;15(6):1642. https:\/\/doi.org\/10.3390\/cancers15061642. PMID: 36980527; PMCID: PMC10046400.","DOI":"10.3390\/cancers15061642"},{"key":"10.32074\/1591-951X-1092_ref52","doi-asserted-by":"crossref","unstructured":"Xu Y, Zhu G, Maroun CA, et al. Programmed Death-1\/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis. Front Immunol. 2021 Apr 7;12:645170. https:\/\/doi.org\/10.3389\/fimmu.2021.645170. PMID: 33897693; PMCID: PMC8058384.","DOI":"10.3389\/fimmu.2021.645170"},{"key":"10.32074\/1591-951X-1092_ref53","doi-asserted-by":"crossref","unstructured":"Wu C, Ke Y, Wan L, et al. Efficacy of immune checkpoint inhibitors differs in various status of carcinoma: a study based on 29 cohorts with 3255 participants. Cancer Immunol Immunother. 2024 Mar 30;73(5):79. https:\/\/doi.org\/10.1007\/s00262-024-03663-z. PMID: 38554165; PMCID: PMC10981616.","DOI":"10.1007\/s00262-024-03663-z"},{"key":"10.32074\/1591-951X-1092_ref54","doi-asserted-by":"crossref","unstructured":"Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the \u2018Immunoscore\u2019 in the classification of malignant tumours. J Pathol. 2014 Jan;232(2):199-209. https:\/\/doi.org\/10.1002\/path.4287. PMID: 24122236; PMCID: PMC4255306.","DOI":"10.1002\/path.4287"},{"key":"10.32074\/1591-951X-1092_ref55","doi-asserted-by":"crossref","unstructured":"Hendry S, Salgado R, Gevaert T, et al. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Adv Anat Pathol. 2017 Nov;24(6):311-335. https:\/\/doi.org\/10.1097\/PAP.0000000000000161. PMID: 28777143; PMCID: PMC5638696.","DOI":"10.1097\/PAP.0000000000000161"},{"key":"10.32074\/1591-951X-1092_ref56","unstructured":"Salgado R, Denkert C, Demaria Set al. International TILs Working Group 2014. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015 Feb;26(2):259-71. https:\/\/doi.org\/10.1093\/annonc\/mdu450. Epub 2014 Sep 11. PMID: 25214542; PMCID: PMC6267863."},{"key":"10.32074\/1591-951X-1092_ref57","doi-asserted-by":"crossref","unstructured":"Almangush A, De Keukeleire S, Rottey S, et al. Tumor-Infiltrating Lymphocytes in Head and Neck Cancer: Ready for Prime Time? Cancers (Basel). 2022 Mar 18;14(6):1558. https:\/\/doi.org\/10.3390\/cancers14061558. PMID: 35326709; PMCID: PMC8946626.","DOI":"10.3390\/cancers14061558"},{"key":"10.32074\/1591-951X-1092_ref58","doi-asserted-by":"crossref","unstructured":"Mandal R, \u015eenbabao\u011flu Y, Desrichard A, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight. 2016 Oct 20;1(17):e89829. https:\/\/doi.org\/10.1172\/jci.insight.89829. PMID: 27777979; PMCID: PMC5070962.","DOI":"10.1172\/jci.insight.89829"},{"key":"10.32074\/1591-951X-1092_ref59","doi-asserted-by":"crossref","unstructured":"Wood O, Woo J, Seumois G, et al. SPARC Consortium. Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors. Oncotarget. 2016 Aug 30;7(35):56781-56797. https:\/\/doi.org\/10.18632\/oncotarget.10788. PMID: 27462861; PMCID: PMC5302866.","DOI":"10.18632\/oncotarget.10788"},{"key":"10.32074\/1591-951X-1092_ref60","doi-asserted-by":"crossref","unstructured":"Balermpas P, Michel Y, Wagenblast J, et al. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer. 2014 Jan 21;110(2):501-9. https:\/\/doi.org\/10.1038\/bjc.2013.640. Epub 2013 Oct 15. Erratum in: Br J Cancer. 2014 Jan 21;110(2):547. PMID: 24129245; PMCID: PMC3899751.","DOI":"10.1038\/bjc.2013.640"},{"key":"10.32074\/1591-951X-1092_ref61","doi-asserted-by":"crossref","unstructured":"Wolf GT, Chepeha DB, Bellile E, et al. University of Michigan Head and Neck SPORE Program. Tumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: a preliminary study. Oral Oncol. 2015 Jan;51(1):90-5. https:\/\/doi.org\/10.1016\/j.oraloncology.2014.09.006. Epub 2014 Oct 3. PMID: 25283344; PMCID: PMC4268429.","DOI":"10.1016\/j.oraloncology.2014.09.006"},{"key":"10.32074\/1591-951X-1092_ref62","doi-asserted-by":"crossref","unstructured":"De Meulenaere A, Vermassen T, Aspeslagh S, et al. TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)? Head Neck Pathol. 2017 Sep;11(3):354-363. https:\/\/doi.org\/10.1007\/s12105-016-0776-8. Epub 2016 Dec 28. PMID: 28032290; PMCID: PMC5550394.","DOI":"10.1007\/s12105-016-0776-8"},{"key":"10.32074\/1591-951X-1092_ref63","doi-asserted-by":"crossref","unstructured":"Li F, Li C, Cai X, Xie Z, Zhou L, Cheng B, Zhong R, Xiong S, Li J, Chen Z, Yu Z, He J, Liang W. The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis. EClinicalMedicine. 2021 Sep 16;41:101134. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101134. PMID: 34585125; PMCID: PMC8452798.","DOI":"10.1016\/j.eclinm.2021.101134"},{"key":"10.32074\/1591-951X-1092_ref64","doi-asserted-by":"crossref","unstructured":"Kuba K, Inoue H, Matsumura S, et al. A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab. Sci Rep. 2022 Dec 29;12(1):22557. https:\/\/doi.org\/10.1038\/s41598-022-27237-0. Erratum in: Sci Rep. 2023 Jan 26;13(1):1472. https:\/\/doi.org\/10.1038\/s41598-023-28598-w. Erratum in: Sci Rep. 2023 May 25;13(1):8467. https:\/\/doi.org\/10.1038\/s41598-023-35683-7. PMID: 36581686; PMCID: PMC9800384.","DOI":"10.1038\/s41598-023-35683-7"},{"key":"10.32074\/1591-951X-1092_ref65","doi-asserted-by":"crossref","unstructured":"Masucci MT, Minopoli M, Carriero MV. Tumor Associated Neutrophils. Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy. Front Oncol. 2019 Nov 15;9:1146. https:\/\/doi.org\/10.3389\/fonc.2019.01146. PMID: 31799175; PMCID: PMC6874146.","DOI":"10.3389\/fonc.2019.01146"},{"key":"10.32074\/1591-951X-1092_ref66","doi-asserted-by":"crossref","unstructured":"Hou A, Hou K, Huang Q, et al. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors. Front Immunol. 2020 May 15;11:783. https:\/\/doi.org\/10.3389\/fimmu.2020.00783. PMID: 32508809; PMCID: PMC7249937.","DOI":"10.3389\/fimmu.2020.00783"},{"key":"10.32074\/1591-951X-1092_ref67","doi-asserted-by":"crossref","unstructured":"Wang Y, Du J, Gao Z, et al. Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy. Br J Cancer. 2023 Mar;128(7):1196-1207. https:\/\/doi.org\/10.1038\/s41416-022-02084-y. Epub 2022 Dec 15. PMID: 36522474; PMCID: PMC10050415.","DOI":"10.1038\/s41416-022-02084-y"},{"key":"10.32074\/1591-951X-1092_ref68","doi-asserted-by":"crossref","unstructured":"Meliante PG, Zoccali F, de Vincentiis M, et al. Diagnostic Predictors of Immunotherapy Response in Head and Neck Squamous Cell Carcinoma. Diagnostics (Basel). 2023 Feb 23;13(5):862. https:\/\/doi.org\/10.3390\/diagnostics13050862. PMID: 36900006; PMCID: PMC10001329.","DOI":"10.3390\/diagnostics13050862"},{"key":"10.32074\/1591-951X-1092_ref69","doi-asserted-by":"crossref","unstructured":"Botticelli A, Cirillo A, d\u2019Amati G, et al. The role of CD73 in predicting the response to immunotherapy in head and neck cancer patients. Pathol Res Pract. 2024 Aug;260:155415. https:\/\/doi.org\/10.1016\/j.prp.2024.155415. Epub 2024 Jun 28. PMID: 38996615.","DOI":"10.1016\/j.prp.2024.155415"},{"key":"10.32074\/1591-951X-1092_ref70","doi-asserted-by":"crossref","unstructured":"Shen A, Ye Y, Chen F, et al. Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma. Front Immunol. 2022 Nov 16;13:969034. https:\/\/doi.org\/10.3389\/fimmu.2022.969034. PMID: 36466881; PMCID: PMC9708745.","DOI":"10.3389\/fimmu.2022.969034"},{"key":"10.32074\/1591-951X-1092_ref71","doi-asserted-by":"crossref","unstructured":"Lin DJ, Ng JCK, Huang L, et al. The immunotherapeutic role of indoleamine 2,3-dioxygenase in head and neck squamous cell carcinoma: A systematic review. Clin Otolaryngol. 2021 Sep;46(5):919-934. https:\/\/doi.org\/10.1111\/coa.13794. Epub 2021 May 30. PMID: 34053179; PMCID: PMC8600953.","DOI":"10.1111\/coa.13794"},{"key":"10.32074\/1591-951X-1092_ref72","doi-asserted-by":"crossref","unstructured":"Botticelli A, Cerbelli B, Lionetto L, et al. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC? J Transl Med. 2018 Aug 6;16(1):219. https:\/\/doi.org\/10.1186\/s12967-018-1595-3. PMID: 30081936; PMCID: PMC6080500.","DOI":"10.1186\/s12967-018-1595-3"},{"key":"10.32074\/1591-951X-1092_ref73","doi-asserted-by":"crossref","unstructured":"Sailer V, Sailer U, Bawden EG, et al. DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients\u2019 survival, immune cell infiltrates, mutational load, and interferon \u03b3 signature. EBioMedicine. 2019 Oct;48:341-352. https:\/\/doi.org\/10.1016\/j.ebiom.2019.09.038. Epub 2019 Oct 15. PMID: 31628024; PMCID: PMC6838413.","DOI":"10.1016\/j.ebiom.2019.09.038"},{"key":"10.32074\/1591-951X-1092_ref74","doi-asserted-by":"crossref","unstructured":"Haddad RI, Seiwert TY, Chow LQM, et al. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. J Immunother Cancer. 2022 Feb;10(2):e003026. https:\/\/doi.org\/10.1136\/jitc-2021-003026. PMID: 35217573; PMCID: PMC8883256.","DOI":"10.1136\/jitc-2021-003026"},{"key":"10.32074\/1591-951X-1092_ref75","doi-asserted-by":"crossref","unstructured":"Serafini MS, Cavalieri S, Licitra L, et al. Association of a gene-expression subtype to outcome and treatment response in patients with recurrent\/metastatic head and neck squamous cell carcinoma treated with nivolumab. J Immunother Cancer. 2024 Jan 30;12(1):e007823. https:\/\/doi.org\/10.1136\/jitc-2023-007823. PMID: 38290766; PMCID: PMC10828850.","DOI":"10.1136\/jitc-2023-007823"},{"key":"10.32074\/1591-951X-1092_ref76","doi-asserted-by":"crossref","unstructured":"Froelich MF, Schoenberg SO, Neumaier M, et al. Status of liquid profiling in precision oncology \u2013 the need for integrative diagnostics for successful implementation into standard care. Journal of Laboratory Medicine, vol. 46, no. 4, 2022, pp. 237-245. https:\/\/doi.org\/10.1515\/labmed-2022-0026","DOI":"10.1515\/labmed-2022-0026"},{"key":"10.32074\/1591-951X-1092_ref77","doi-asserted-by":"crossref","unstructured":"Haselmann V, Hedtke M, Neumaier M. Liquid Profiling for Cancer Patient Stratification in Precision Medicine-Current Status and Challenges for Successful Implementation in Standard Care. Diagnostics (Basel). 2022 Mar 19;12(3):748. https:\/\/doi.org\/10.3390\/diagnostics12030748. PMID: 35328301; PMCID: PMC8947441.","DOI":"10.3390\/diagnostics12030748"},{"key":"10.32074\/1591-951X-1092_ref78","doi-asserted-by":"crossref","unstructured":"Kabzinski J, Kucharska-Lusina A, Majsterek I. RNA-Based Liquid Biopsy in Head and Neck Cancer. Cells. 2023; 12(14):1916. https:\/\/doi.org\/10.3390\/cells12141916","DOI":"10.3390\/cells12141916"},{"key":"10.32074\/1591-951X-1092_ref79","doi-asserted-by":"crossref","unstructured":"Kulasinghe A, Kenny L, Punyadeera C. Circulating tumour cell PD-L1 test for head and neck cancers. Oral Oncol. 2017 Dec;75:6-7. https:\/\/doi.org\/10.1016\/j.oraloncology.2017.10.011. Epub 2017 Oct 19. PMID: 29224824.","DOI":"10.1016\/j.oraloncology.2017.10.011"},{"key":"10.32074\/1591-951X-1092_ref80","doi-asserted-by":"crossref","unstructured":"Tamari K, Minami K, Tatekawa S, et al. Circulating Plasma Exosomal PD-L1 Predicts Prognosis of Head and Neck Squamous Cell Carcinoma After Radiation Therapy. Adv Radiat Oncol. 2023 Aug 15;9(2):101353. https:\/\/doi.org\/10.1016\/j.adro.2023.101353. PMID: 38405303; PMCID: PMC10885579.","DOI":"10.1016\/j.adro.2023.101353"},{"key":"10.32074\/1591-951X-1092_ref81","doi-asserted-by":"crossref","unstructured":"Cirillo A, Zizzari IG, Botticelli A, et al. Int J Mol Sci. 2023 Apr 12;24(8):7114. https:\/\/doi.org\/10.3390\/ijms24087114.","DOI":"10.3390\/ijms24087114"},{"key":"10.32074\/1591-951X-1092_ref82","doi-asserted-by":"crossref","unstructured":"Desrichard A, Kuo F, Chowell D, et al. Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas. J Natl Cancer Inst. 2018 Dec 1;110(12):1386-1392. https:\/\/doi.org\/10.1093\/jnci\/djy060. PMID: 29659925; PMCID: PMC6292793.","DOI":"10.1093\/jnci\/djy060"},{"key":"10.32074\/1591-951X-1092_ref83","doi-asserted-by":"crossref","unstructured":"Burcher KM, Burcher JT, Inscore L, et al. A Review of the Role of Oral Microbiome in the Development, Detection, and Management of Head and Neck Squamous Cell Cancers. Cancers (Basel). 2022 Aug 25;14(17):4116. https:\/\/doi.org\/10.3390\/cancers14174116. PMID: 36077651; PMCID: PMC9454796.","DOI":"10.3390\/cancers14174116"},{"key":"10.32074\/1591-951X-1092_ref84","doi-asserted-by":"crossref","unstructured":"Peng Z, Cheng S, Kou Y, et al. The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1\/PD-L1 Immunotherapy in Gastrointestinal Cancer. Cancer Immunol Res. 2020 Oct;8(10):1251-1261. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-1014. Epub 2020 Aug 27. PMID: 32855157.","DOI":"10.1158\/2326-6066.CIR-19-1014"},{"key":"10.32074\/1591-951X-1092_ref85","doi-asserted-by":"crossref","unstructured":"Xue X, Li R, Chen Z, et al. The role of the symbiotic microecosystem in cancer: gut microbiota, metabolome, and host immunome. Front Immunol. 2023 Aug 24;14:1235827. https:\/\/doi.org\/10.3389\/fimmu.2023.1235827. PMID: 37691931; PMCID: PMC10484231.","DOI":"10.3389\/fimmu.2023.1235827"},{"key":"10.32074\/1591-951X-1092_ref86","doi-asserted-by":"crossref","unstructured":"Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018 Jan 5;359(6371):91-97. https:\/\/doi.org\/10.1126\/science.aan3706. Epub 2017 Nov 2. PMID: 29097494.","DOI":"10.1126\/science.aan3706"},{"key":"10.32074\/1591-951X-1092_ref87","doi-asserted-by":"crossref","unstructured":"Ferris RL, Blumenschein G, Harrington K, et al. Abstract CT022: Evaluation of oral microbiome profiling as a response biomarker in squamous cell carcinoma of the head and neck: Analyses from CheckMate 141. Cancer Res 1 July 2017; 77 (13_Supplement): CT022. https:\/\/doi.org\/10.1158\/1538-7445.AM2017-CT022","DOI":"10.1158\/1538-7445.AM2017-CT022"},{"key":"10.32074\/1591-951X-1092_ref88","doi-asserted-by":"crossref","unstructured":"Vellanki PJ, et al., Evaluation of the correlation between antibiotic use and survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (R\/M HNSCC) treated with immune checkpoint inhibitors (ICIs).. JCO 38, 6509-6509(2020). https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.6509","DOI":"10.1200\/JCO.2020.38.15_suppl.6509"}],"container-title":["Pathologica"],"original-title":[],"link":[{"URL":"https:\/\/www.pathologica.it\/article\/view\/1344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T07:41:59Z","timestamp":1749195719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pathologica.it\/article\/view\/1344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":88,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,4]]}},"URL":"https:\/\/doi.org\/10.32074\/1591-951x-1092","relation":{},"ISSN":["1591-951X"],"issn-type":[{"value":"1591-951X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"article-number":"2"}}